Home  >  News
you can get e-magazine links on WhatsApp.Click here
Pioma_Lactic
Biotechnology + Font Resize -

COVAX exercises option to buy 176.5 million more doses of Moderna’s Covid vaccine for low income countries

Cambridge, Mass
Saturday, October 16, 2021, 11:00 Hrs  [IST]

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that Gavi, the Vaccine Alliance has exercised its option to purchase an additional 176.5 million doses of the Moderna Covid-19 vaccine for the COVAX Facility.

Of these additional doses, 116.5 million doses are expected to be delivered in the first quarter of 2022 and 60 million doses are expected to be delivered in the second quarter of 2022. All doses are offered at Moderna’s lowest tiered price, in line with the company’s global access commitments.

COVAX retains the option to purchase 116.5 million doses for delivery in the third quarter of 2022 and an additional 116.5 million doses for delivery in the fourth quarter of 2022. These doses are in addition to the 34 million doses purchased for delivery in the fourth quarter of 2021.

COVAX has options to purchase an additional 233 million doses in second half of 2022

The 210 million doses purchased to date by COVAX are 100 µg per dose. Recently, Moderna has requested authorization of a 50 µg dose as a booster from the same vial which would significantly increase the number of usable doses procured by COVAX at no additional cost. The average purchase price across all doses purchased to date is just under $10 per 100 µg dose, equating to less than $5 per 50 µg dose.

“I would like to thank COVAX for their tireless work to deliver our vaccine to low income countries. We support COVAX’s mission to ensure broad, affordable and equitable access to Covid-19 vaccines and this agreement is an important pillar of our access strategy,” said Stéphane Bancel, chief executive officer of Moderna. “We believe our vaccine can play an important role in addressing the needs of low income countries given its combination of high phase 3 efficacy against Covid-19, strong durability in the real-world evidence, and superior storage and handling conditions. We recognize that access to all vaccines, including ours, continues to be a challenge in many parts of the world which is one of the reasons why we have worked hard to enable a 50 µg booster dose, which will increase the number of usable booster doses available to low income countries at no additional cost.”

Through this long-term agreement, UNICEF and its procurement partners have been provided access to up to 500 million doses of the Moderna Covid-19 vaccine through 2022. This agreement covers the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries. The Company is in discussions to allocate and supply to self-financing participants in the future. COVAX is a global initiative co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO, to ensure equitable access to Covid-19 vaccines for all countries, regardless of income levels.

This supply agreement with Gavi on behalf of the COVAX Facility is an important pillar of Moderna’s comprehensive plan to bring vaccines to as many people as possible around the world. On October 8, Bancel published a letter on Moderna’s commitment to global vaccine access. Moderna also recently announced an investment of up to $500 million to build a state-of-the-art mRNA facility in Africa with the goal of producing up to 500 million doses of vaccines each year at the 50 µg dose level.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |